|
| related topics |
| {product, candidate, development} |
| {cost, operation, labor} |
| {product, liability, claim} |
| {operation, international, foreign} |
| {gas, price, oil} |
| {financial, litigation, operation} |
| {product, market, service} |
| {operation, natural, condition} |
|
|
The Company s business will be adversely affected if it is unable to obtain regulatory approval for new product introductions or to expand sales of existing products into new markets.
The Company is exposed to the risks of operating a global business, including risks associated with exchange rate fluctuations, legal and regulatory changes and the impact of regional and global economic disruptions, which could have an adverse effect on the Company s business.
The development of new hyaluronan products entails substantial risk of failure and uncertainty related to timing, and a significant amount of the Company s anticipated growth is dependent on its ability to develop, manufacture and market new product applications for hyaluronan.
The Company is dependent on the marketing and development support from corporate partners for the sales growth of the Hyaluronan Division, and the Company s business could be adversely affected if the Company s strategic alliances fail to develop or market products as planned.
If the Company is unable to scale up manufacturing operations in the event of a significant increase in customer demand, the Company s business could be adversely affected.
An interruption in the Company s manufacturing activities could adversely affect the Company s relations with its customers.
There is uncertainty and risk that FeHA will not be returned to the market, which would negatively impact the Company s future revenue potential.
The markets for the Company s dental products are very competitive, and the Company s results of operations and financial condition could be adversely affected if it cannot maintain or increase the market share of these products.
The Company may be subject to product liability claims and other legal proceedings which could have a material adverse effect on the Company s business, financial condition and results of operations.
Full 10-K form ▸
|
|
| related documents |
| 28626--9/13/2007--LIFECORE_BIOMEDICAL_INC |
| 8855--9/4/2007--AMERICAN_LOCKER_GROUP_INC |
| 899866--2/23/2009--ALEXION_PHARMACEUTICALS_INC |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 75829--3/28/2008--PALL_CORP |
| 855683--3/17/2009--MILESTONE_SCIENTIFIC_INC/NJ |
| 1101026--5/18/2009--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 1436083--7/20/2009--New_Millennium_Products |
| 1114200--2/28/2007--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 1026650--3/7/2008--ERESEARCHTECHNOLOGY_INC_/DE/ |
| 949858--3/16/2006--SONUS_PHARMACEUTICALS_INC |
| 814453--2/29/2008--NEWELL_RUBBERMAID_INC |
| 780127--1/7/2009--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 50104--2/26/2007--TESORO_CORP_/NEW/ |
| 896622--2/27/2009--APTARGROUP_INC |
| 744825--3/31/2009--AMERICAN_SHARED_HOSPITAL_SERVICES |
| 92769--2/11/2010--SPECTRUM_CONTROL_INC |
| 896622--2/28/2007--APTARGROUP_INC |
| 1026650--3/9/2007--ERESEARCHTECHNOLOGY_INC_/DE/ |
| 1158387--3/20/2009--VISCOUNT_SYSTEMS_INC |
| 109198--3/30/2010--TJX_COMPANIES_INC_/DE/ |
| 27096--9/13/2006--DATASCOPE_CORP |
| 202058--8/26/2008--HARRIS_CORP_/DE/ |
| 1012019--3/12/2010--RUSH_ENTERPRISES_INC_\TX\ |
| 7431--2/26/2010--ARMSTRONG_WORLD_INDUSTRIES_INC |
| 911649--3/31/2006--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 718924--12/28/2007--SPAN_AMERICA_MEDICAL_SYSTEMS_INC |
| 853695--3/31/2009--DRI_CORP |
| 20--3/9/2007--K_TRON_INTERNATIONAL_INC |
|